

LABELED PROTEIN AND ITS PRODUCING METHOD, LABELING
COMPOUND TO BE USED IN THE METHOD, AND METHOD FOR
ANALYZING FUNCTION OF GENES

insert

BACKGROUND OF THE INVENTION

The present invention relates to a labeled protein and its producing method and a labeling compound to be used in the method. Also the present invention relates to a method for analyzing function of genes.

For labeling of protein expressed in cell-free translation systems and living cells is used generally a radiolabeling method that involves incorporating an amino acid labeled with a radioactive element such as ^{35}S , ^3H , ^{14}C or the like into the translation product. However, amino acids may be used in reactions other than protein synthesis so that it happens that substances other than the translation product may be also labeled. On the other hand, the labeling method specific to the translation product includes the following method. To the ϵ -amino group of lysine, biotin is covalently linked, and the product is further linked through an ester linkage to tRNA having an anticodon for lysine to synthesize a complex (biotin-lysine-tRNA), which is put into a cell-free translation system to biotinate the translation

09737731.1 1980

product. The translation product is electrophoresed and then transferred on a membrane, and allowed to chemiluminesce with an alkali phosphatase by using a fusion protein of the alkaline phosphatase and streptoavidine. This chemiluminescence is recorded using X-ray film or the like for identifying the translation product (Promega, (1993) Technical Bulletin, No. 182, p.2). However, this method suffers from extreme instability of the synthesized biotin-lysine-tRNA (for 6 months at -70°C) and is expensive. Further, there is the problem that the procedure for identification is complicated and time-consuming. This is disadvantageous in automation for processing on a large scale. The translated protein is modified by biotin at a plurality of lysine side chains so that there is the possibility that its function and structure vary from the original one.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a methodology which satisfies conditions such as 1) simplicity, 2) economically competitiveness, 3) long-term stability, and 4) no adverse influence on the function and structure of the translation product in labeling of translated protein in a cell-free translation system and living cells.

As a result of intensive investigation with

003741.434000

view to overcoming the above-described problems, it has now been found that puromycin or its derivatives binds or bind to the C-terminal of a translated protein in a final concentration of 10 to 0.01 μM . It has also been found that the compound obtained by chemically linking a fluorescent substance such as fluorescein to puromycin binds to the C-terminal of the translated protein like puromycin and use of this enables one to identify proteins. That is, by adding the fluorescent puromycin to a cell-free translation system to carry out reaction, and then subjecting the product to gel electrophoresis, the gel without further processing can be read by a fluorescent image analyzer to identify the translated protein without difficulty. The present invention has been completed based on these findings.

Thus the present invention provides a labeling compound for labeling a protein, which comprises a label portion comprising a label substance and an acceptor portion comprising a compound having an ability of binding to a C-terminal of a synthesized protein when protein synthesis is carried out in a cell-free protein synthesis system or in a living cell, and a protein having the labeling compound attached to its C-terminal.

According to another aspect of the present invention, there is provided a method for producing

0973751-121800

Table 1. Mean values of the variables measured during the 60-min test

	Pretest	Test
Heart rate (beats min ⁻¹)	78 ± 10	159 ± 15*
Systolic blood pressure (mmHg)	118 ± 10	160 ± 15*
Diastolic blood pressure (mmHg)	78 ± 10	100 ± 15*
Stroke volume (ml)	100 ± 10	110 ± 15*
Cardiac output (l min ⁻¹)	7.8 ± 1.0	12.2 ± 1.5*
Oxygen consumption (l min ⁻¹)	2.5 ± 0.5	3.5 ± 0.5*
Ventilatory equivalent	15.0 ± 2.0	20.0 ± 2.0*
Respiratory quotient	0.85 ± 0.05	0.85 ± 0.05
Lactate concentration (mmol l ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Blood glucose concentration (mmol l ⁻¹)	5.0 ± 0.5	4.5 ± 0.5
Free fatty acid concentration (mmol l ⁻¹)	0.5 ± 0.1	1.0 ± 0.1*
Plasma insulin concentration (mU l ⁻¹)	1.0 ± 0.2	1.5 ± 0.2*
Plasma growth hormone concentration (ng ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma cortisol concentration (nmol l ⁻¹)	10.0 ± 2.0	15.0 ± 2.0*
Plasma epinephrine concentration (pmol l ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma norepinephrine concentration (pmol l ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma renin activity (ng ml ⁻¹ h ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Angiotensin II concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma aldosterone concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma vasopressin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma endothelin-1 concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma nitric oxide concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma prostaglandin E ₂ concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma thromboxane A ₂ concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma serotonin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma histamine concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma substance P concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma calcitonin receptor-related peptide concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma cholecystikinin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma bombesin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma somatostatin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma oxytocin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma vasopressin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma angiotensinogen concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma renin substrate concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma angiotensin-converting enzyme concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma bradykinin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma endothelin-1 concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma nitric oxide concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma prostaglandin E ₂ concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma thromboxane A ₂ concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma serotonin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma histamine concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma substance P concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma calcitonin receptor-related peptide concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma cholecystikinin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma bombesin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma somatostatin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma oxytocin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma vasopressin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma angiotensinogen concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma renin substrate concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma angiotensin-converting enzyme concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma bradykinin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma endothelin-1 concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma nitric oxide concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma prostaglandin E ₂ concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma thromboxane A ₂ concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma serotonin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma histamine concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma substance P concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma calcitonin receptor-related peptide concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma cholecystikinin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma bombesin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma somatostatin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma oxytocin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma vasopressin concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma angiotensinogen concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma renin substrate concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma angiotensin-converting enzyme concentration (pg ml ⁻¹)	1.0 ± 0.2	2.5 ± 0.3*
Plasma bradykinin concentration (

[illegible][illegible]

[illegible][illegible][illegible]

a

Fig. 2 shows the chemical structure of puromycin bound to a fluorescent substance. V is Fluorpur and VI is Fluorthiopur.

³⁵S-methionine.

illustrating binding of puromycin bound to a fluorescent substance to the C-terminal of thioredoxin. Labeling was performed by reaction in a cell-free transcription-translation system of *Escherichia coli* in the presence of 0.036, 0.072, 0.18, 0.36, 0.72, or 1.44 μM of Fluorpur or Fluorthiopur at 37°C for 30 minutes. The ^{Fig. 4A}~~upper~~ electrophoretogram indicates the influence of Fluorpur

Fig. 4B is a photograph of an (FluorPur) concentration and the middle illustrating

electrophoretogram, illustrates the influence of FluorS-Pur concentration. The arrow

indicates the position of apparent molecular weight of 12 kDa in the full-length protein of thioredoxin. Fig. 4C is a photograph of the

lower electrophoretogram, corresponding to the gel

stained with CBB, which is a dye usually used for staining proteins, after detecting the gel of the

upper electrophoretogram by fluorimetry. The leftmost

lane in the lower electrophoretogram corresponds to a

supernatant of disrupted cells that were obtained by

incubating *E. coli* strain BL21(DE3) harboring a

plasmid (pT-Trx) containing T7 promoter and a coding

region for coding *E. coli* thioredoxin (135 amino acid

residues, molecular weight: 14 kDa, apparent molecular

weight: 12 kDa) in LB medium in the presence of

chloramphenicol (final concentration: 34 µg/ml) at

37°C, and causing mass expression of thioredoxin by

addition of IPTG. This indicates mass expression of

thioredoxin at the position of apparent molecular

weight of 12 kDa.

DETAILED DESCRIPTION OF THE INVENTION

The labeling compound of the present invention comprises a "label portion" that comprises a label substance and an "acceptor portion" that comprises a compound having an ability of binding to the

0073751.121800

far as the compound has an ability of binding to the C-terminal of a synthesized protein when synthesis (translation) of the protein is carried out in a cell-free protein synthesis system or in a living cell. Usually, the acceptor portion is a compound in which a compound containing a chemical structure skeleton that resembles a nucleic acid or its repeated structure and an amino acid or a compound having a chemical structure skeleton that resembles an amino acid are chemically bound to each other (nucleic acid derivative). There can be utilized those having an amido linkage as the chemical bond such as puromycin, and 3'-N-aminoacylpuromycin aminonucleoside (PANS-amino acid), for example, PANS-Gly, which contains glycine as the amino acid moiety, PANS-Val, which contains valine as the amino acid moiety, PANS-Ala, which contains alanine as the amino acid moiety, and the like and all the other PANS-amino acids corresponding to all the amino acids.

3'-N-Aminoacyladenine aminonucleoside (AANS-amino acid) having as the chemical bond an amido linkage formed by condensation with dehydration between the amino group of 3'-aminoadenosine and a carboxyl group of an amino acid, for example, AANS-Gly, which contains glycine as the amino acid moiety, AANS-Val, which contains valine as the amino acid moiety, AANS-Ala, which contains alanine as the amino acid

003727-121000

[illegible]

THE

[illegible][illegible]

Compound IV in Fig. 1).

The ability of the compound which constitutes the acceptor portion to bind to the C-terminal of a protein when the synthesis (translation) of the protein is carried out in a cell-free protein synthesis system or in a living cell can be evaluated by carrying out the synthesis of a protein in the cell-free protein synthesis system or in the living cell in the presence of that compound and measuring the production of a peptidyl compound.

The cell-free protein synthesis system or the living cell is not limited to particular one as far as protein synthesis can proceed when a nucleic acid encoding the protein is added or introduced therein. As the cell-free protein synthesis system, there can be used a cell-free protein synthesis system of procaryote or eucaryote, for example, cell-free protein synthesis systems of *E. coli*, rabbit reticulocyte, wheat germ and the like. As the protein synthesis system may be used either a cell-free transcription-translation system or a cell-free translation system depending on whether the nucleic acid used as a template is DNA or RNA. As the living cell, there may be used a cell of procaryotes such as *E. coli* or eucaryotes.

The labeling compound can be produced by linking the label portion and the acceptor portion by

a known chemical linking method.

As an example in which the label portion comprises a radioactive substance, first puromycin and rC- β -amidite are coupled and then the protective group is removed to synthesize rCpPur. In a similar manner, dCpPur and dUpPur can be synthesized. Then these compounds may be phosphorylated by T4 polynucleotide kinase in the presence of γ - ^{33}P -ATP to prepare a labeling compound of which the hydroxyl group at the 5'-end of the nucleic acid is labeled with ^{33}P .

Also, fluorescent labeling compounds, for example, Fluorpur (Compound ^V~~V~~ in Fig. 2) and Fluorthiopur (Compound ^{VI}~~V~~ in Fig. 2), in which a fluorescent dye, for example, fluorescein, as the label portion and a compound comprising a nucleic acid bound to an amino acid or a compound having a chemical structure skeleton resembling an amino acid, for example, puromycin as the acceptor portion are linked to each other through a chemical bond, can be obtained by coupling puromycin and fluoredite and then removing the protective group.

The protein to which the labeling compound is added at the C-terminal thereof is not limited to a particular one.

The protein to which the labeling compound is added at the C-terminal thereof can be produced by the production method of the present invention described

09737751-121800

hereinbelow.

The production method for the above-described protein according to the present invention comprises the step of carrying out synthesis of a protein in a cell-free protein synthesis system or in a living cell in the presence of a labeling compound comprising a label portion comprising a label substance and an acceptor portion comprising a compound having an ability of binding to a C-terminal of a synthesized protein when protein synthesis is carried out in the cell-free protein synthesis system or in the living cell, the labeling compound being present at a concentration effective for the labeling compound to bind to the C-terminal of the synthesized protein.

As described above, the compound that constitutes the acceptor portion of the labeling compound has an ability of binding to a C-terminal of a synthesized protein when protein synthesis is carried out in a cell-free protein synthesis system or in a living cell so that the labeling compound could inhibit the protein synthesis depending on its concentration.

For example, puromycin (Compound I in Fig. 1) is known to inhibit the protein synthesis of bacteria (Nathans, D. (1964) Proc. Natl. Acad. Sci. USA, 51, 585-592; Takeda, Y. et al. (1960) J. Biochem., 48, 169-177) and animal cells (Ferguson, J.J. (1962)

00373751-121800

Biochim. Biophys. Acta, 57, 616-617; Nemeth, A.M. & de la Haba, G.L. (1962) J. Biol. Chem., 237, 1190-1193). The chemical structure of puromycin resembles that of aminoacyl tRNA and reacts with peptidyl tRNA that is bound to the P-site of ribosome and liberated from the ribosome as peptidyl puromycin, resulting in termination of the protein synthesis (Harris, R.J. (1971) Biochim. Biophys. Acta, 240, 244-262).

However, in the present invention, the protein synthesis is carried out in the presence of the labeling compound at a concentration effective for the labeling compound to bind to the C-terminal of the synthesized protein, that is, at a concentration where the protein synthesis in a cell-free protein synthesis system or in a living cell is not inhibited and where it can be linked in an amount allowing detection to the C-terminal of the protein, thereby linking the labeling compound to the C-terminal of the protein.

Though not desiring to be bound to any theory, the reason why the labeling compound is linked to the C-terminal of the synthesized protein would presumably be that in protein synthesis in the presence of the labeling compound at a low concentration such that the protein synthesis is not inhibited, when a termination codon comes to the A-site of a ribosome, the labeling compound is linked to the C-terminal of protein by the action of peptidyltransferase in competition with the

0973754-121800

termination factor.

The concentration which is effective for the labeling compound to bind to the C-terminal of the synthesized protein can be determined by the method described in the examples below with respect to an actually used system.

For example, examination of labeling of the translated protein labeled with the above-described labeling compound in the presence of a plasmid containing a promoter and coding regions for various proteins, for example, T7 promoter and a coding region for thioredoxin in a cell-free transcription-translation system of *E. coli*, shows the concentration range (0.1 to 1 μ M) where $^{33}\text{P-rCpPur}$ is evidently linked to the C-terminal of the full-length protein of thioredoxin (apparent molecular weight: 12 kDa) (Fig. 3). The radiolabeling of the full-length protein of thioredoxin with $^{33}\text{P-rCpPur}$ or the like can be confirmed in a cell-free transcription-translation system containing nuclease treated rabbit reticulocyte lysate or wheat germ lysate. Similarly confirmed optimal concentrations of Fluorpur and Fluorthiopur necessary for radiolabeling are 0.3 to 50 μ M in the system containing nuclease treated rabbit reticulocyte lysate and 10 to 50 μ M in the case of the system containing wheat germ lysate.

If the label portion is replaced by various

Q

Examination of fluorescent labeling of the translated protein labeled with the above-described fluorescent labeling compound in the presence of a plasmid containing a promoter and coding regions for various proteins, for example, T7 promoter and a coding region for thioredoxin in a cell-free transcription-translation system of *E. coli*, shows the concentration range (0.3 to 1.5 μM) where Fluorpur or Fluorthiopur is evidently linked to the C-terminal of the full-length protein of thioredoxin (apparent molecular weight: 12 kDa) (Fig. 4). The fluorescent labeling of the full-length protein of thioredoxin with Fluorpur and Fluorthiopur can be confirmed also in a cell-free transcription-translation system containing nuclease treated rabbit reticulocyte lysate or wheat germ lysate. Similarly confirmed optimal concentrations of Fluorpur and Fluorthiopur necessary for fluorescent labeling are 0.3 to 50 μM in the

system containing nuclease treated rabbit reticulocyte lysate and 10 to 50 μ M in the case of the system containing wheat germ lysate.

The present invention further provides a method for analyzing a function of a gene, comprising the steps of: adding a nucleic acid containing the gene to a cell-free protein synthesis system as a template; carrying out protein synthesis in the presence of the labeling compound to obtain a protein having the labeling compound attached to the C-terminal of the protein, the labeling compound being present at a concentration effective for the labeling compound to bind to the C-terminal of the synthesized protein; and analyzing a function of the labeled protein.

The analysis method of the present invention utilizes the method for producing a labeled protein according to the present invention. More specifically, it is the same as the method for producing the labeled protein except for the steps of adding a nucleic acid containing a gene to a cell-free protein synthesis system as a template and analyzing a function of the labeled protein.

As the gene for analyzing its function may be used those accumulated by genome analysis.

The nucleic acid containing a gene may be any of genomic DNA, cDNA, and a transcription product of a

003737E1-121800

[illegible]

THE

THE

THE

THE

therefore, the identification and function analysis of a protein expressed by the gene can be practiced rapidly, accurately, and economically.

EXAMPLES

Hereafter, the present invention will be described more concretely by examples. However, the following examples are construed as being an aid for obtaining concrete knowledge of the present invention but in no way limit the scope of the present invention.

Example 1

Preparation of a Labeling compound and Labeling of a Protein Using the Compound

<1> Preparation of Labeling compound

(a) Synthesis of rCpPur (ribocytidyl(3'→5')puromycin (II))

Material: Puromycin (3'-[α-amino-p-methoxyhydro-cinnamamido]-3'-deoxy-N,N'-dimethyladenosine, I) was purchased from Sigma; rC-β-amidite (N⁴-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-tert-butyldimethylsilyl)-cytidine-3'-O-[O-(2-cyanoethyl)-N,N'-diisopropylphosphoramidite]), dC-β-amidite (N⁴-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-deoxycytidine-3'-O-[O-(2-cyanoethyl)-N,N'-diisopropylphosphoramidite]), and dU-β-amidite (5'-O-(4,4'-dimethoxytrityl)-2'-

deoxyuridine-3'-O-[O-(2-cyanoethyl)-N,N'-diisopropyl-phosphoramidite]) were each purchased from Nippon Perceptive; tetrazole was purchased from Nippon Millipore; fluorinated tetrabutylammonium was purchased from Aldrich; QAE-Sephadex was purchased from Pharmacia; and silica gel for chromatography was purchased from Merck.

Method: Puromycin (50 mg, 92 μ mol) was dissolved in 2 ml of dry pyridine, evaporated under reduced pressure and dehydrated. This procedure was repeated 3 times. To this were added 15 ml of 4% tetrazole/acetonitrile solution and rC- β -amidite, and the mixture was stirred at room temperature. The reaction was monitored by silica gel thin layer chromatography (TLC, developing solvent: chloroform:methanol = 9:1). Usually, the reaction was completed in 1 day. After the reaction was over, the solvent was removed under reduced pressure, and 3 ml of a solution of 0.1 M iodine in tetrahydrofuran/pyridine/water = 80:40:2 was added thereto. The resulting phosphite triester was oxidized while stirring at room temperature. After 1 hour and half, the solvent was removed under reduced pressure and the residue was extracted with chloroform. After the extract was dried over anhydrous magnesium sulfate, the solvent was removed under reduced pressure. This was applied to silica

gel column chromatography and eluted with chloroform/methanol = 90:10. Ribocytidyl puromycin (CpPur) with a protective group was eluted at Rf 0.32 on the silica gel TLC (development solvent: chloroform:methanol = 9:1). Then, the protective groups were removed. Ribocytidylpuromycin with a protective group was treated initially with 0.5 ml of aqueous 80% acetic acid solution at room temperature for 1 hour to effect detritylation. After removing acetic acid under reduced pressure, 0.5 ml of a mixed solution of concentrated aqueous ammonia/ethanol = 2:1 was added to remove a β -cyanoethyl group and a benzoyl group. After allowing to stand at room temperature for 15 hours, the solvent was removed under reduced pressure, and to the residue was added 0.5 ml of 1 M tetrabutylammonium fluoride in tetrahydrofuran to deprotect the t-butyldimethylsilyl group attached to the 2'-OH group. After 30 minutes, the solvent was removed under reduced pressure and the residue was applied to QAE-Sephadex column chromatography and eluted with a linear gradient of 0 to 0.5 M triethylamine carbonate. The eluted solutions were collected and lyophilized. Thus, 10 mg of ribocytidylpuromycin was obtained. The synthetic product was identified as ribocytidylpuromycin because nuclease P1 digestion gave the same amounts of cytidine and puromycin 5'-phosphoric acid and a

0973751.1E1800

molecular ion of $[M+H]^+$ appears at m/z 777 in MALDI/TOF mass spectrometry. dCpPur (deoxycytidyl (3'→5')puromycin (III) and dUpPur (deoxyuridyl(3'→5')puromycin (IV) were synthesized and identified, respectively, in the same manner as the above-described rCpPur from dC-β-amidite (N^4 -benzoyl-5'-O-4,4'-dimethoxytrityl)-2'-deoxycytidine-3'-O-[O-(2-cyanoethyl)- N,N' -diisopropylphosphoramidite]) and dU-β-amidite (5'-O-4,4'-dimethoxytrityl)-2'-deoxyuridine-3'-O-[O-(2-cyanoethyl)- N,N' -diisopropylphosphoramidite]) and puromycin as starting materials.

(b) Preparation of fluoresceinylphosphopuromycin (Fluorpur, V) and fluoresceinylthiophosphopuromycin (Fluorthiopur, VI)

Material: Puromycin was purchased from Sigma, fluoredate (6- N -carboxy-di- O -pivaloyl-fluorescein-hexyl- O -(2-cyanoethyl)-(N,N' -diisopropyl)-phosphoramidite) was purchased from Nippon Perceptive, tetrazole was purchased from Nippon Millipore, TETD (tetraethylthiuram disulfide) was purchased from ABI, and silica gel for chromatography was purchased from Merck.

Method: Puromycin (26 mg, 48 μmol) was dissolved in 3 ml of dry pyridine, evaporated under reduced pressure and dehydrated. This procedure was repeated 3 times. To this were added 5 ml of 4%

tetrazole/acetonitrile solution and fluoredate, and the mixture was stirred at room temperature. The reaction was monitored by silica gel thin layer chromatography (TLC, developing solvent: chloroform:methanol = 9:1). Usually, the reaction was completed in 2 hours. After the reaction was over, the solvent was removed under reduced pressure and 2 ml of a solution of 0.1 M iodine in tetrahydrofuran/pyridine/water = 80:40:2 was added thereto. The resulting phosphite triester was oxidized while stirring at room temperature. After 1 hour and half, the solvent was removed under reduced pressure and the residue was extracted with chloroform. After the extract was dried over anhydrous magnesium sulfate, the solvent was removed under reduced pressure. This was applied to silica gel column chromatography and eluted with chloroform/methanol = 90:10. Fluorpur with a protective group was eluted at Rf 0.26 on the silica gel TLC (development solvent: chloroform:methanol = 9:1). Then, the protective groups were removed. Fluorpur with a protective group was added to 1 ml of a mixed solution of concentrated aqueous ammonia/ethanol = 2:1 to remove a β -cyanoethyl group, thus giving 7 mg of Fluorpur (V). The synthetic product was identified as Fluorpur (V) because ultraviolet and visible rays absorption spectra of its

008727-1-1300

003727-1-1900

solution at pH 9 appear at 272 nm (attributed to puromycin moiety) and 494 nm (attributed to fluorescein moiety) and a molecular ion of $[M+H]^+$ appears at m/z 1010 in MALDI/TOF mass spectrometry. Fluorthiopur was synthesized in the same manner as Fluorpur except that after the coupling of puromycin and fluoredite, 1 ml of acetonitrile solution of TETD was added instead of iodine and stirred at room temperature for 30 minutes to sulfurate the phosphite triester. After the reaction was over, the solvent was removed under reduced pressure and the residue was extracted with chloroform. The extract was dried over anhydrous magnesium sulfate and the solvent was removed under reduced pressure. This was applied to silica gel chromatography and eluted with chloroform/methanol = 90:10. Fluorthiopur with a protective group was eluted at R_f 0.33 on the silica gel TLC (development solvent: chloroform:methanol = 9:1). Then, the protective groups were removed. Fluorthiopur with a protective group was added to 1 ml of a mixed solution of concentrated aqueous ammonia/ethanol = 2:1 to remove a β -cyanoethyl group, thus giving 6 mg of Fluorthiopur (VI). The synthetic product was identified as Fluorthiopur (VI) because ultraviolet and visible rays absorption spectra of its solution at pH 9 appear at 272 nm (attributed to puromycin moiety) and 494 nm (attributed to

<2> Preparation of Plasmid

<3> Method for Labeling Protein

(a) Labeling of Protein Using rCpPur

rCpPur (30 pmol) was phosphorylated by T4 polynucleotide kinase (10 units) in the presence of γ -³³P-ATP (9.25 MBq). The reaction was carried out under the condition of 37°C for 1 hour. After the reaction was over, the reaction mixture was heated at 70°C for 20 minutes to inactivate the enzyme.

Labeling reaction was carried out using a cell-free transcription-translation system of E. coli.

The reaction mixture (25 μ l) of the cell-free transcription-translation system of *E. coli* had the following composition: 7.5 μ l of *E. coli* S30 extract (containing T7 RNA polymerase), 10 μ l of *E. coli* S30 premix, 2.5 μ l of an amino acid mixed solution, 1 μ l of an RNase inhibitor, 1 μ g of plasmid (thioredoxin), and 0.0003 to 0.3 μ M (final concentration) of the 33 P-rCpPur described above. As a control, the reaction was carried out also in a system containing 35 S-methionine (1.2 μ M). After the reaction was carried out at 37°C for 30 minutes, precipitation was performed with acetone. A buffer solution (pH 8) containing 1% SDS was added to the precipitate, and then heated at 90°C for 5 minutes for dissolution, separated by SDS-15% polyacrylamide gel electrophoresis, and analyzed using an image analyzer (Fuji Photo Film, BAS 2000). Fig. 3 shows the results of examination of labeling of thioredoxin with 33 P-rCpPur. When the concentration of 33 P-rCpPur was 0.3 μ M, a distinct band corresponding to the full-length thioredoxin was detected at the position of apparent molecular weight of 12 kDa. The result shows that 33 P-rCpPur is linked to the C-terminal of thioredoxin. The band with an apparent molecular weight of 12 kDa was detected even when labeled with 35 S-methionine (final concentration: 1.2 μ M) (Fig. 3). In a similar manner, it was confirmed that 33 P-dCpPur

(b) Fluorescent Labeling of a Protein With Fluorpur and Fluorthiopur

a

Fluorothiorpur. For both Fluorpur and Fluorothiorpur in a concentration ranges of 0.36 to 1.44 μ M, fluorescent bands were detected at the position of apparent molecular weight of 12 kDa indicated by an arrow (~~the upper and middle electrophoretograms in Fig. 4~~ ^{Fig. 4A and 4B}). The results show that Fluorpur and Fluorothiorpur are linked to the C-terminal of the full-length protein (apparent molecular weight: 12 kDa) (cf. the band of mass expressed thioredoxin in the ^{Fig. 4C} ~~lower electrophoretogram~~) of thioredoxin. Also, it revealed that Fluorothiorpur was incorporated more or less efficiently as compared with Fluorpur.

The fluorescent labeling of the full-length protein of thioredoxin with Fluorpur and Fluorothiorpur was confirmed also in a cell-free transcription-translation system containing nuclease treated rabbit reticulocyte lysate or wheat germ lysate. The respective optimal concentrations of Fluorpur and Fluorothiorpur necessary for fluorescent labeling were 0.3 to 50 μ M in the system containing nuclease treated rabbit reticulocyte lysate and 10 to 50 μ M in the case of the system containing wheat germ lysate.